Menu
Search
|

Menu

Close
X

Capricor Therapeutics Inc CAPR.OQ (NASDAQ Stock Exchange Capital Market)

1.34 USD
-- (--)
As of Jul 18
chart
Previous Close 1.34
Open --
Volume --
3m Avg Volume 40,368
Today’s High --
Today’s Low --
52 Week High 4.25
52 Week Low 0.90
Shares Outstanding (mil) 29.11
Market Capitalization (mil) 41.05
Forward P/E 20.33
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
3
FY16
4
FY15
6
EPS (USD)
FY18
-0.136
FY17
-0.139
FY16
-1.022
FY15
-0.811
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
20.33
32.86
Price to Sales (TTM)
vs sector
18.78
8.16
Price to Book (MRQ)
vs sector
3.56
4.20
Price to Cash Flow (TTM)
vs sector
16.00
22.15
Total Debt to Equity (MRQ)
vs sector
32.05
17.38
LT Debt to Equity (MRQ)
vs sector
32.05
13.24
Return on Investment (TTM)
vs sector
19.66
13.13
Return on Equity (TTM)
vs sector
145.19
15.07

EXECUTIVE LEADERSHIP

Frank Litvack
Independent Executive Chairman of the Board, Since 2013
Salary: --
Bonus: --
Linda Marban
President, Chief Executive Officer, Director, Since 2014
Salary: $232,909.00
Bonus: --
Anthony Bergmann
Chief Financial Officer, Principal Accounting Officer, Since 2018
Salary: --
Bonus: --
Karen Krasney
Executive Vice President, General Counsel, Since 2013
Salary: $243,750.00
Bonus: --
Thomas Copmann
Vice President - Regulatory Affairs and Drug Development, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

8840 Wilshire Blvd Fl 2
BEVERLY HILLS   CA   90211-2606

Phone: +1310.3583200
Site: capricor.com

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.

SPONSORED STORIES